Literature DB >> 18221075

Soluble epoxide hydrolase: a novel target for the treatment of hypertension.

Xiang Fang1.   

Abstract

Epoxide hydrolases are a group of enzymes that convert the epoxide group of chemical compounds to corresponding diols by the addition of water. Soluble epoxide hydrolase (sEH, formerly referred to as cytosolic epoxide hydrolase), which is widely distributed in mammalian tissues, is the primary enzyme responsible for the conversion of epoxyeicosatrienoic acids (EETs), the bioactive lipid mediators formed from arachidonic acid by cytochrome P450 epoxygenase, to their corresponding diols. EETs, but not their diols, are endogenous anti-hypertensive eicosanoids. Disruption of the sEH gene in male mice decreases blood pressure, and inhibition of sEH decreases blood pressure in several experimental hypertensive models. Potent selective sEH inhibitors have been developed, and these sEH inhibitors have potential to become a novel class of anti-hypertensive drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18221075     DOI: 10.2174/157489006775244227

Source DB:  PubMed          Journal:  Recent Pat Cardiovasc Drug Discov


  13 in total

1.  Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.

Authors:  A Ulu; Se Appt; C Morisseau; S H Hwang; P D Jones; T E Rose; H Dong; J Lango; J Yang; H J Tsai; C Miyabe; C Fortenbach; M R Adams; B D Hammock
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

3.  The differences in brain stem transcriptional profiling in hypertensive ISIAH and normotensive WAG rats.

Authors:  Larisa A Fedoseeva; Leonid O Klimov; Nikita I Ershov; Vadim M Efimov; Arcady L Markel; Yuriy L Orlov; Olga E Redina
Journal:  BMC Genomics       Date:  2019-05-08       Impact factor: 3.969

4.  Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo.

Authors:  Suman Kundu; Talat Roome; Ashish Bhattacharjee; Kevin A Carnevale; Valentin P Yakubenko; Renliang Zhang; Sung Hee Hwang; Bruce D Hammock; Martha K Cathcart
Journal:  J Lipid Res       Date:  2012-11-15       Impact factor: 5.922

5.  An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Anamitra Ghosh; Michele M Comerota; Debin Wan; Fading Chen; Nicholas E Propson; Sung Hee Hwang; Bruce D Hammock; Hui Zheng
Journal:  Sci Transl Med       Date:  2020-12-09       Impact factor: 17.956

6.  Role of epoxyeicosatrienoic acids as autocrine metabolites in glutamate-mediated K+ signaling in perivascular astrocytes.

Authors:  Haruki Higashimori; Víctor M Blanco; Vengopal Raju Tuniki; John R Falck; Jessica A Filosa
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-15       Impact factor: 4.249

Review 7.  Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.

Authors:  Karen M Wagner; Cindy B McReynolds; William K Schmidt; Bruce D Hammock
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

Review 8.  Redox Regulation of Soluble Epoxide Hydrolase-Implications for Cardiovascular Health and Disease.

Authors:  Rebecca Charles; Philip Eaton
Journal:  Cells       Date:  2022-06-15       Impact factor: 7.666

Review 9.  Stress, Genes, and Hypertension. Contribution of the ISIAH Rat Strain Study.

Authors:  Olga E Redina; Arcady L Markel
Journal:  Curr Hypertens Rep       Date:  2018-06-16       Impact factor: 5.369

10.  Inhibition of Soluble Epoxide Hydrolase 2 Ameliorates Diabetic Keratopathy and Impaired Wound Healing in Mouse Corneas.

Authors:  Haijing Sun; Patrick Lee; Chenxi Yan; Nan Gao; Jiemei Wang; Xianqun Fan; Fu-Shin Yu
Journal:  Diabetes       Date:  2018-04-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.